<DOC>
	<DOC>NCT00229723</DOC>
	<brief_summary>The primary purpose of this study is to assess the effectiveness of ZD1839 250 mg and 500 mg when given either concomitantly or as maintenance to a standard therapy of radiotherapy (X-rays) plus chemotherapy (cisplatin) in terms of local disease control (progression-free) rate at 2 years.</brief_summary>
	<brief_title>IRESSAâ„¢ (Gefitinib) With Cisplatin Plus Radiotherapy for the Treatment of Previously Untreated Unresected Late Stage III/IV Non-Metastatic Head and Neck Squamous Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Squamous Cell</mesh_term>
	<mesh_term>Head and Neck Neoplasms</mesh_term>
	<mesh_term>Neoplasms, Squamous Cell</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Histologically or cytologically confirmed stage III or IVA squamous cell carcinoma of the head and neck No prior surgery or chemotherapy/biological therapy/radiation therapy Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) Life expectancy of more than 12 weeks Cancers of the nasal space, oral cavity and larynx; or certain lung diseases. Abnormal blood chemistry; uncontrolled respiratory, cardiac, hepatic, or renal disease; or coexisting malignancies.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>Head and Neck Squamous Cell Carcinoma</keyword>
	<keyword>Head and Neck Squamous Cell Cancer</keyword>
	<keyword>Squamous Cell Carcinoma</keyword>
	<keyword>Squamous Cell Cancer</keyword>
</DOC>